Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
942.55
3.35 (0.36%) Zydus Lifesciences informs about press release
Date: 13-01-2026Zydus Lifesciences has informed that it enclosed a copy of press release dated January 13, 2026, titled ‘Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)’.
The above information is a part of company’s filings submitted to BSE.